ARCHIVES

Two Phase II Studies of Ibrutinib Deliver High Response Rates

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Give Dox-SL Conditional Approval; Ok Zoladex

February 24, 1995

NCI Statisticians Disputes Bross Claim

April 27, 1979

NCI RFP Available.

February 11, 2000

Are Lab Budgets Excessive? Views On Intramural Program

April 21, 1995

NIH Defends NCI Sponsored Travel

December 3, 2010

Clinical Practice Guidelines Don’t Meet IOM Standards

June 26, 2013